IL17A and autoimmune disease: While a variety of IL-17/IL-23 antagonists are currently being developed for the treatment of autoimmune diseases (131), safe and effective modification of Th17 signaling in cancer therapy will require a more thorough understanding of the forces which underlie Th17 differentiation, recruitment, and interaction with malignant cells.